Electronic nose technology can facilitate an accurate diagnosis of sarcoidosis

Electronic nose technology can facilitate an accurate diagnosis of sarcoidosis

08 April 2022

1 minute of reading


Source / Information


Disclosures: van der Sar does not disclose any material financial information. Please see the study for relevant financial information from all other authors.


We were unable to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Electronic nose technology accurately distinguished sarcoidosis patients from those with interstitial lung disease and healthy controls, the researchers reported. Chest.

“Currently, the diagnosis of sarcoidosis is difficult due to the large differences in clinical presentation that often require invasive diagnostic procedures such as biopsies,” Iris G. van der Sar, MD, The graduate student in the respiratory medicine department at Erasmus Medical Center in Rotterdam, the Netherlands, told Healio. “There is a high need for more accurate, non-invasive and rapid diagnostics in patients suspected of sarcoidosis.”


The data were derived from van der Sar IG, et al. Chest. 2022; doi: 10.1016 / j.chest.2021.10.025.

The single-center, cross-sectional study included 252 patients with sarcoidosis (mean age, 53.1 years; 53.2% men), 317 patients with ILD (mean age, 70 years; 61.5% men), and 48 healthy controls. (mean age, 36.5 years; 31.3% men). Researchers evaluated all patients ‘exhaled breath using SpiroNose (Breathomix), an electronic nasal device (eNose), and collected clinical features from the patients’ medical records.

The training cohort included 168 sarcoidosis patients and 32 healthy controls, and the validation cohort included 84 sarcoidosis patients and 16 healthy controls.

The eNose device was able to distinguish sarcoidosis patients from healthy controls (area under the curve = 1), other ILDs (AUC = 0.87) and hypersensitivity pneumonitis (AUC = 0.88) in the cohort validation. For the training cohort, the AUCs were 1 to distinguish sarcoidosis patients from healthy controls, 0.90 from other ILDs, and 0.95 from hypersensitivity pneumonitis. According to the researchers, there were no distinct differences between the exhaled breath of sarcoidosis patients with and without lung involvement, pulmonary fibrosis, multiple organ involvement, disease-supported diagnosis, and immunosuppressive treatment.

Researchers observed different respiratory profiles between patients with a slightly elevated soluble interleukin (IL) -2 receptor level and those with a very high soluble IL-2 receptor level with a median cutoff of 772 U / mL. and an AUC of 0.78.

According to van der Sar, “the accuracy of the eNose technology … is much higher than other diagnostic tests used in clinical practice for patients with sarcoidosis.”

Moving forward, the results of this study need to be validated in an outpatient cohort, van der Sar told Healio.

“Creating a diagnostic algorithm will allow clinicians to use eNose technology in clinical decision making in the future,” said van der Sar.

For more information:

Iris G. van der Sar, MD, he can be reached at igvandersar@erasmusmc.nl.

Leave a Comment

Your email address will not be published.